Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma

F. H. Dexeus, C. J. Logothetis, A. Sella, L. Finn

Research output: Contribution to journalArticlepeer-review

Abstract

A prospective randomized trial tested the hypothesis that interferon and cytotoxic chemotherapy delivered sequentially would be synergistic and would increase the response rate in metastatic renal cell carcinoma. Thirty-six patients were entered and randomized to chemotherapy only (5-fluorouracil, doxorubicin, mitomycin and cis-platin) vs interferon alternating with the same chemotherapy. Only 4 of 32 evaluable patients (13%), 2 in each arm, had a major response. Three patients in the alternating arm had minor responses. Complete, partial, and minor responses totaled 7 (22%). All four patients whose only disease was lung metastasis had some evidence of response (p = 0.001). Interferon alternating with chemotherapy did not appear to improve the major response rate over chemotherapy alone. Responses in metastatic renal cell carcinoma appear confined to a favorable subset of patients.

Original languageEnglish
Pages (from-to)350-354
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number4
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Dive into the research topics of 'Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this